Insulin

Anji Pharma Fully Enrolls Cohort at Leading Beijing Hospital to Ready Global ANJ900 Pivotal Program in Asia

Health, Diabetes, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, DREAM, Patient, Insulin, Publication, Plasma, Kidney, SGLT2, Type 2 diabetes, Pharma, Efficiency, Metformin, Functional constipation, Pharmaceutical industry
Tuesday, November 30, 2021 - 2:00pm

Anji Pharma (Anji), an emerging global medicines company, today announced full enrollment for a confirmatory study in Chinese healthy participants for a delayed-release formulation of metformin called ANJ900.

Key Points: 
  • Anji Pharma (Anji), an emerging global medicines company, today announced full enrollment for a confirmatory study in Chinese healthy participants for a delayed-release formulation of metformin called ANJ900.
  • Anji plans to report topline data from this study in January 2022.
  • The full enrollment of the Beijing study is an important milestone for our DREAM-T2D program and our multi-national clinical operations organization, noted Greg Dombal, Anjis Global Head of Development.
  • Anji Pharma is a clinical-stage company dedicated to bringing life-changing therapies to patients across the globe.

Fractyl Health Announces the FDA’s Authorization of Expanding the Revitalize-1 Study’s Sample Size

Biotechnology, FDA, Other Health, Diabetes, Health, General Health, Other Science, Medical Devices, Research, Science, Clinical Trials, Patient, Insulin, Health, European Union, ADAS, Prediabetes, Diabetes, Disease, Therapy, Program, Particle-size distribution, Lists of diseases, Risk, Union, FDA, Mortality, Metformin, Pharmaceutical industry
Tuesday, November 30, 2021 - 1:00pm

The Revita DMR system has been tested in multiple early pilot clinical studies in approximately 300 patients with various stages of T2D.

Key Points: 
  • The Revita DMR system has been tested in multiple early pilot clinical studies in approximately 300 patients with various stages of T2D.
  • Based on this earlier clinical experience, the company also announced today a deepening of its clinical development program in T2D, the Revitalize T2D program.
  • Fractyl Health is focused on pioneering a new approach to the treatment of T2D.
  • Fractyl Health is a private organ-editing metabolic therapeutics company based in Lexington, MA.

AMF Medical Receives FDA Breakthrough Device Designation for Its Sigi™ Insulin Management System

Patient, Insulin, Review, US Foods, Technology, Diabetes, MD, CHUV, Board of directors, Board, CO, Smartphone, FDA, Clinical trial, Food, Medical device, Pharmaceutical industry
Tuesday, November 30, 2021 - 12:00pm

ECUBLENS,Switzerland, Nov. 30, 2021 /PRNewswire/ --AMF Medical is proud to announce that its SigiInsulin Management System, for diabetes mellitus treatment, has met the criteria and has been granted Breakthrough Device Designation by the US Food and Drug Administration.

Key Points: 
  • ECUBLENS,Switzerland, Nov. 30, 2021 /PRNewswire/ --AMF Medical is proud to announce that its SigiInsulin Management System, for diabetes mellitus treatment, has met the criteria and has been granted Breakthrough Device Designation by the US Food and Drug Administration.
  • Sigi can be programmed to deliver basal and bolus insulin at both set and variable rates.
  • Sigi is also smaller, lighter and more convenient than current insulin delivery systems.
  • This Breakthrough Device Designation will expedite the development of Sigi and prioritize its review in future FDA regulatory submissions.It is a huge step forward in bringing Sigi to market to improve insulin management."

PharmaCyte Biotech Launches Malignant Ascites Program with Commencement of Pivotal Preclinical Study

Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Cell, Private Securities Litigation Reform Act, Insulin, Pancreatic cancer, Cancer, Technology, Breathe Me, Diabetes, Neoplasm, Capsule, Form, Abdomen, Malignancy, IND, Breast, Ifosfamide, Abdominal cavity, Program, Immortalised cell line, U.S. Securities and Exchange Commission, Medicine, Ascites, Stomach, NASDAQ, Biotechnology, FDA, Form 10-K, Coronavirus Scientific Advisory Board (Turkey), PMCB, Colon, Liver, Pharmaceutical industry, Medical device, Medical imaging
Tuesday, November 30, 2021 - 6:05am

PharmaCytes Chief Executive Officer, Kenneth L. Waggoner, said, We are enthusiastic to relaunch our malignant ascites program and resume our work on developing a treatment for malignant ascites.

Key Points: 
  • PharmaCytes Chief Executive Officer, Kenneth L. Waggoner, said, We are enthusiastic to relaunch our malignant ascites program and resume our work on developing a treatment for malignant ascites.
  • We plan to conduct another preclinical study in Germany with Heidelberg Pharma that mimics an earlier study which showed the production of malignant ascites can be delayed by our cancer treatment.
  • We will be using the same animal study model that Dr. Lhr used in the earlier study that showed promise.
  • Malignant ascites is fluid secreted by abdominal tumors which includes liver, breast, colon, stomach, intestine, ovarian and uterine cancers.

Infusion Pumps Market is Expected to Grow at a CAGR of 9.53% and is Anticipated to Reach USD 20.75 Billion by 2026, Estimates DelveInsight

Patient, Skin, Insulin, DASH, Boston Scientific, Technology, Nursing, US Foods, Diabetes, Infusion pump, Hospital, Population, CAGR, Hormone, Tandem, Pump, Nutrient, Prevalence, USD, Fresenius (company), COVID-19, Pain, Chronic pain, CareFusion, FDA, Medicine, Growth, Medtronic, Baxter International, Food, Medical device
Monday, November 29, 2021 - 4:30pm

LAS VEGAS, Nov. 29, 2021 /PRNewswire/ -- DelveInsight's Infusion Pump Market Insights and Forecast report provide the current and forecast Infusion Pumps market, upcoming innovation in the devices, individual market shares, challenges, drivers and barriers, market trends, and key competitors in the Infusion Pumps market.

Key Points: 
  • LAS VEGAS, Nov. 29, 2021 /PRNewswire/ -- DelveInsight's Infusion Pump Market Insights and Forecast report provide the current and forecast Infusion Pumps market, upcoming innovation in the devices, individual market shares, challenges, drivers and barriers, market trends, and key competitors in the Infusion Pumps market.
  • Some of the salient features from the Infusion Pump Market report:
    As per an analysis by DelveInsight, North America is expected to dominate the overall Infusion Pumps market during the forecast period.
  • DelveInsight estimates that Global Infusion Pumps Market was valued at USD 12.67 billion in 2020, growing at a CAGR of 9.53% during the forecast period from 2021 to 2026, to reach USD 20.75 billion.
  • To get a deeper understanding of the driving factors related to the Infusion Pumps market, get a snapshot of the Infusion Pumps Market Dynamics

Infusion Pumps Market is Expected to Grow at a CAGR of 9.53% and is Anticipated to Reach USD 20.75 Billion by 2026, Estimates DelveInsight

Patient, Skin, Insulin, DASH, Boston Scientific, Technology, Nursing, US Foods, Diabetes, Infusion pump, Hospital, Population, CAGR, Cancer, Tandem, Pump, Prevalence, Nutrient, Hormone, USD, Fresenius (company), Food, COVID-19, Chronic pain, Pain, CareFusion, FDA, LAS, Medicine, Medtronic, Baxter International, Growth, Medical device
Monday, November 29, 2021 - 4:30pm

LAS VEGAS, Nov. 29, 2021 /PRNewswire/ -- DelveInsight's Infusion Pump Market Insights and Forecast report provide the current and forecast Infusion Pumps market, upcoming innovation in the devices, individual market shares, challenges, drivers and barriers, market trends, and key competitors in the Infusion Pumps market. 

Key Points: 
  • LAS VEGAS, Nov. 29, 2021 /PRNewswire/ -- DelveInsight's Infusion Pump Market Insights and Forecast report provide the current and forecast Infusion Pumps market, upcoming innovation in the devices, individual market shares, challenges, drivers and barriers, market trends, and key competitors in the Infusion Pumps market.
  • Some of the salient features from the Infusion Pump Market report:
    As per an analysis by DelveInsight, North America is expected to dominate the overall Infusion Pumps market during the forecast period.
  • DelveInsight estimates that Global Infusion Pumps Market was valued at USD 12.67 billion in 2020, growing at a CAGR of 9.53% during the forecast period from 2021 to 2026, to reach USD 20.75 billion.
  • To get a deeper understanding of the driving factors related to the Infusion Pumps market, get a snapshot of the Infusion Pumps Market Dynamics

Insulin-Science Based App Launches During National Diabetes Month

People, Prediabetes, Insulin, Technology, App Store (iOS/iPadOS), Diabetes, Eating, Health, Habit, Goal, Family, Google Play, Meal, Pharmaceutical industry
Friday, November 26, 2021 - 1:33pm

CLIFFSIDE PARK, N.J., Nov. 26, 2021 /PRNewswire/ --November is National Diabetes Month, the perfect time to take a closer look at our health.

Key Points: 
  • CLIFFSIDE PARK, N.J., Nov. 26, 2021 /PRNewswire/ --November is National Diabetes Month, the perfect time to take a closer look at our health.
  • If you thought that living with diabetes was just about counting carbs and taking medication, you should know, there's a lot more to the story.
  • Our goal is to help those living with diabetes and pre-diabetes and are therefore pleased to announce our launch in both the Apple App Store and the Google Play Store.
  • DishQuo is a low-cost, science-based meal planning app, making eating for diabetic health simple, timesaving and enjoyable.

Biotechnology Instruments Market Trends Analysis Report 2021 - 2028: Increasing Demand for Point-of-care Tests and Devices - ResearchAndMarkets.com

Biotechnology, Medical Devices, Health, Technology, Software, Government, Insulin, Adoption, Peptide, CAGR, POC, Prevalence, USD, Laser, Waters Corporation, COVID-19, Oligonucleotide, Sartorius AG, Biotechnology, Chromatography, Novasep, Growth, Medical device, Fine chemical, Animal
Friday, November 26, 2021 - 11:40am

The "Biotechnology Instruments Market Size, Share & Trends Analysis Report By Product (Life Science Consumables, IVD Instruments, Medical Lasers, Lab Automation Instruments), By End-use, By Region, And Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Biotechnology Instruments Market Size, Share & Trends Analysis Report By Product (Life Science Consumables, IVD Instruments, Medical Lasers, Lab Automation Instruments), By End-use, By Region, And Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • The global biotechnology instruments market size is expected to reach USD 106.75 billion by 2028.
  • The market is expected to expand at a CAGR of 12.66% from 2021 to 2028.
  • The market is collectively driven by technological advancements, advantages offered by laser therapy, growing prevalence of target diseases, rising geriatric population, and increasing demand for Point-Of-Care (POC) tests and devices.

Health Research Foundation Announces Recipient of Its Medal of Honour

Patient, Health, Insulin, Hospital for Sick Children (Toronto), HRF, Medal of Honor, Student, QC, Leadership, ISCB Senior Scientist Award, Child, Health policy, Policy, ICES, Disease, CHES, The Hospital, Medical device, Pharmaceutical industry
Wednesday, November 24, 2021 - 5:30pm

Ottawa, Ontario--(Newsfile Corp. - November 24, 2021) - The Health Research Foundation (HRF) of Innovative Medicines Canada today awarded its prestigious Medal of Honour to Dr. Astrid Guttmann at the HRF's annual stakeholder conference.

Key Points: 
  • Ottawa, Ontario--(Newsfile Corp. - November 24, 2021) - The Health Research Foundation (HRF) of Innovative Medicines Canada today awarded its prestigious Medal of Honour to Dr. Astrid Guttmann at the HRF's annual stakeholder conference.
  • Her research focuses on the use of population-based administrative data to improve health outcomes for children and youth facing a variety of complex disorders.
  • Dr. Stephen Scherer, Chief of Research, SickKids
    "The HRF is extremely pleased to honour Dr. Guttmann with its Medal of Honour.
  • The Health Research Foundation (HRF) of Innovative Medicines Canada is a non-profit organization that invests in health research in Canadian academic centres and promotes the benefits and values of research-driven health innovation in Canada.

Terumo Corporation and Diabeloop SA Enter Into Comprehensive Strategic Partnership Agreement to Expand Their Diabetes Care Offerings

Patient, Blood transfusion, Insulin, CGM, CEO, Technology, Diabetes, Personality, Dexcom, Partnership, Solution, Peritoneal dialysis, DM, GLOBE, AID, PARIS, Freedom, Automated insulin delivery systems, CEA-Leti: Laboratoire d'électronique des technologies de l'information, Quality of life, Medical device, Pharmaceutical industry
Thursday, November 18, 2021 - 12:00am

It analyzes the data in real time, and decides whether to maintain current insulin settings or adjust insulin delivery.

Key Points: 
  • It analyzes the data in real time, and decides whether to maintain current insulin settings or adjust insulin delivery.
  • Based on this strategic partnership agreement, the two companies will accelerate and strengthen collaboration for AID systems.
  • "It is our great pleasure to enter into this comprehensive strategic partnership agreement.
  • "We are thrilled to reinforce our partnership with global leader Terumo with this new agreement and expand our contribution to personalized diabetes management via Diabeloop's interoperable solution.